Speciality:

Board certified in Ophthalmology with subspecialty training in disease and surgery of retina & vitreous.
Special interest in medical and surgical management of diabetic retinopathy, macular degeneration, retinal vascular disorder, macular pucker, macular hole, and retinal detachment.

Experienced in intravitreal injection of Lucentis, Eylea, Avastin and Ozurdex for treatment of Diabetic retinopathy, Macular Degeneration and other indicated eye conditions.

Skilled in surgical management of retina diseases as well as an experienced suture-less clear cornea phacoemulsification cataract surgery. 

Well trained in medical management of glaucoma and other anterior segment conditions.

Academic History

1984-1989 The University of Texas at Arlington
Arlington, Texas
Graduated, June 1989
Bachelor of Science in Biology

1989-1993 The University of Texas Medical School at Houston
Houston, Texas
Graduated, June 1993
Doctor of Medicine
*Outstanding Achievement in Ophthalmology Research Program

1993-1994 Saint Joseph Hospital Department of General Surgery
Houston, Texas
General Surgery Internship
*Intern of the Year

1994-1995 Gap year
General practice/ Locum tenens

1995-1996 University of Maryland Department of Ophthalmology
Baltimore, Maryland
Resident in Ophthalmology
*Chief Resident

Guest Speaker:

Management of ocular injury in the ER setting
Diabetic retinopathy: Diagnosis and treatment
The aging eye

1998-2000 Charles A. Garcia, MD and Associates, Maurice B. Landers, III, MD
Saint Joseph Hospital, Retina Vascular Center
Houston, Texas
Retina Fellowship (Medical & Surgical) Retina Associate (2000- 2002)

2000-2002 Charles A. Garcia, MD and Associate
Houston, Texas
Private Practice

July 2002-May 2006 Victoria Eye Center
Victoria, Texas
Private Practice

July 2006-July 2008 Valley Retina Institute
McAllen, Texas
Private Practice

July 2008- Present Valley Vitreoretinal Consultants
Mission, Texas
Private Practice

Publication:

Su, J.; Garcia, C.A. M.D.; Chu, H.H. M.D.; “Retinal Pigmented EpitheliumTransplantation” University of Texas Medical School Research Abstract. p.29, 1990

Su, J. M.D.; Steidl, S. M.D.; Liu, S. M.D.; Gupta, P. M.D.; “Inhibition of Intraocular Fibrin Formation During Vitrectomy Following Infusion of Desmopressin” ARVO, 1997

Liu, S. M.D.; Su, J. M.D.; Hemady, R. M.D.; “ Corneal Melting after Avulsion of a Molteno Shunt Plate” J. Glaucoma, Vol 6, No. 6: 357- 358, 1997

Liu, S. M.D.; Su, J. M.D.; Steidl, S. M.D.; Gupta, P. M.D.; “Inhibition of Postvitrectomy Fibrin Using Troxerutin” Retina, Vol 18, No. 3, 1998

Sub-Investigator – A Phase 3 B, Randomized, Active Controlled, Double-Masked, Single Dummy, Multi-Center Comparative Trial, In Parallel Groups, To Compare The Safety and Efficacy of Intravitreous Injections of Macugen Given Every 6 Weeks For 54 Weeks (To Be Extended To 102 Weeks As Indicated) Plus Sham Photodynamic Clinical Research: Therapy (PDT), To Macugen Plus PDT With Visudyne, In Subjects Curriculum Vitae, Page 3 Yu-Tang James Su, M.D. With Predominantly Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Protocol EOP1012. Version Date 28 August 2006. Study Closed.

Sub-Investigator – A Phase 2/3 Randomized, Controlled, Double- Masked, Multi-Center, Comparative Dose-Finding Trial, in Parallel of Groups, to Compare the Safety and Efficacy of Intravitreous Injections of 0.3, 0.03 or 0.003mg Pegaptanib Sodium (Macugen), Given as often as Every 6 Weeks for 3 years, to Sham Injections, in Subjects with Diabetic Macular Edema (DME) Involving the Center of the Macula. Protocol EOP1013. Version Date 11 December 2006. Study Closed.

Sub-Investigator – A Phase IV, Open-label, Multi-center Trial of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects with Subfoveal Neovascular Age-related Macular Degeneration (AMD) Initially Treated with a Different Modality Resulting in Maculopathy Improvement. Protocol EOP1023. Version Date 22 May 2006. Sub-Investigator –A Trial to Assess the safety and Tolerability of repeated Doses of Intravitreal Administration of Two VEGF Trap Formulations in Subjects with Neovascular Age-Related Macular Degeneration. Protocol VGFT-OD-0603.

Sub-Investigator–A Phase III, Double-Masked, Multi-Center, Randomized, Sham-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus. Protocol FVF4170g. Sub-Investigator – A Phase 3 B, Multicenter Study to Evaluate the Safety and Tolerability of Ranibizumab in Naïve and Previously Treated Subjects with Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD). Protocol FVF3689g. Version Date 16 February 2006.

Sub-Investigator – A Randomized, Double-Masked, Parallel Group, Multicenter, Dose-Finding Comparison of the Safety and Efficacy and ASI-001A 0.5 μg/day and ASI-001B 0.2 μg/day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects with Diabetic Macular Edema. Protocol C-01-05-001.Version Date 5 March 2007.

Sub-Investigator – A Mutlicenter, Randomized, Placebo-Controlled, Double-Masked, Parallel-Group, Dose-Ranging Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy: The MIVI III (Microplasmin For Vitreous Injection III) Trial. Protocol TG-MV-003. Version Date 16 May 2007.

Sub- Investigator-A Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion and One for Branch Retinal Vein Occlusion. Version 3.1. Dated 26 October 2005.

Licensed: Texas

Board Certified: American Board of Ophthalmology
Member of American Academy of Ophthalmology
Member of Texas Medical Association
Member of Texas Ophthalmological Association
Member of American Society of Retina Specialist